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Binding of a single-chain Fv antibody to Escherichia
coli b-galactosidase (b-gal) is known to stabilize the
enzyme and activate several inactive point mutants,
historically called antibody-mediated enzyme for-
mation mutants. To understand the nature of this
activation, we have determined by electron cryo-
microscopy the structure of the complex between
b-gal and the antibody scFv13R4. Our structure
localizes the scFv13R4 binding site to the crevice be-
tween domains 1 and 3 in each b-gal subunit. The
mutations that scFv13R4 counteracts are located be-
tween the antibody binding site and the active site of
b-gal, at one end of the TIM-barrel that forms domain
3 where the substrate lactose is hydrolyzed. The
mode of binding suggests how scFv stabilizes both
the active site of b-gal and the tetrameric state.
INTRODUCTION
Recent advances in microscopes and detectors have resulted in
single-particle electron cryo-microscopy (cryo-EM) becoming a
powerful technique in structural biology. The ability to image
macromolecules by cryo-EM and obtain a structure with a min-
imal amount of protein and without the need for crystals is a
big advantage. We have been studying b-galactosidase (b-gal)
by single-particle cryo-EM with the goal of reaching atomic res-
olution (Chen et al., 2013; Henderson et al., 2011). b-gal is a
tetrameric enzyme, encoded by the lacZ gene of the lac operon,
and it has been biochemically and structurally well studied (Dug-
dale et al., 2010; Juers et al., 2012). Early genetic studies had
shown that coexpression or mixing of completely inactive poly-
peptides from certain pairs of mutant b-gal molecules could
produce an active enzyme. This phenomenon, called a-comple-
mentation, is explained by the contribution of residues from two
adjacent subunits in the tetramer to each active site, thus
restoring the enzymatic activity when regions that include the
nonmutated residues from adjacent subunits combine to form
one active site. These genetic studies also identified mutants
of b-gal that regain enzymatic activity upon incubation with
particular antibodies, collectively called antibody-mediated
enzyme formation (AMEF) mutants (Celada and Strom, 1972;
Messer and Melchers, 1970). For example, the AMEF959 genediffers from the wild-type lacZ gene by one base substitution
at codon 358: GAG (E) to AAG (K), thus changing a side chain
with a negative charge into a side chain with a positive charge
(Laden et al., 2002). This E358K mutant and several other
AMEF mutants are point mutations. Two hypotheses have
been put forward to explain their loss of activity (Laden et al.,
2002). One hypothesis suggested that the enzyme remained
tetrameric but that its active site was disrupted by the mutation
and then restored by direct binding of the antibody. The second
hypothesis attributed loss of activity to dissociation of the nor-
mally tetrameric enzyme into inactive dimers, with restoration
of activity by binding of antibody to an epitope at the tetramer
interface (de Macario et al., 1978). Binding of antibodies also in-
creases the thermostability of wild-type b-gal (Melchers and
Messer, 1970). Although both hypotheses have some experi-
mental support, the evidence is not conclusive and may depend
on the mutant in question.
Martineau et al. (1998) used the AMEF mutants to identify
single-chain antibodies that can be expressed in the cytoplasm
of Escherichia coli in a functional form in large quantities. A
typical antibody has an intradomain disulfide bond, but when ex-
pressed in the reducing environment of the cytoplasm of E. coli
the bond is not formed, frequently resulting in unfolded or unsta-
ble antibodies. Disulfide bonds linking the two b sheets in each
antibody domain are normally formed in the endoplasmic reticu-
lum or bacterial periplasm. To overcome this limitation, Marti-
neau et al. (1998) developed a system for genetic selection of
folded and functional antibody fragments in the cytoplasm using
the AMEF mutants, with the goal of optimizing the expression,
stability, and affinity of a single-chain Fv antibody domain. Start-
ing with an Fv domain from a phage antibody library, they carried
out four rounds of antibody mutation and selection using error-
prone polymerase chain reaction in an E. coli strain coexpressing
the mutant b-gal AMEF959 (E358K). By selecting for the ability to
grow better in a galactose medium, they succeeded in obtaining
a functional scFv fragment that expressed well and had a final
dissociation constant of 2 mM (Martineau et al., 1998).
Using b-gal and scFv, we aimed to (1) observe and map by
single-particle cryo-EM the location of the binding site for the
28 kDa scFv fragment and (2) explain how the antibody activates
the enzyme. By mixing the enzyme and the antibody, we were
able to form the b-gal:scFv complex and obtain images that
gave an excellent 3D map. The map clearly shows the location
of the scFv binding site and favors an explanation of antibody-
mediated activation by a direct stabilization of the region of the
protein where the AMEF mutations occur. This type of analysis
of antibody-protein complexes is widely applicable for exampleStructure 22, 621–627, April 8, 2014 ª2014 The Authors 621
Figure 1. Typical Regions of Raw Micro-
graphs and Selected Images of Single
Particles
Field of view in typical micrographs of (A) the
b-gal:Fv complex (image 19.59.55), (B) b-gal
without antibody (image 01.49.47), and (C) Fv
antibody alone (image 13.35.50). We also show a
gallery of some selected particles of (D) b-gal
alone and (E) complex. Because of the back-
ground of free scFv antibodies with 28 kDa MW,
the images of the complex look noisy. Scale,
3,100 A˚ edge in (A–C) and 260 A˚ for each panel
in (D) and (E).
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Antibody-Mediated Activation of b-galactosidaseto virus-neutralizing antibodies and other small structures of
marginal stability, such as mutant p53 tumor suppressor pro-
teins or HIV Env.
RESULTS
The dissociation constant between the scFv13R4 antibody
domain and b-gal was estimated previously (Martineau et al.,
1998) at 2 mM. At a b-gal concentration of1 mg/ml, the enzyme
active sites would be expected to be present at 9 mM. With the
Fv concentration at 20 mM, the occupancy of each site,
assuming four sites per tetramer, would be expected to be
90%. Assuming no cooperativity in binding, we would expect
about half the complexes to be b-gal:(Fv)4 and half b-gal:(Fv)3,
with a smaller number of dimeric and monomeric stoichiome-
tries. The resulting maps are completely consistent with the ex-
pected stoichiometry and occupancy.
Raw images of b-gal:scFv13 complex were much noisier than
images of b-gal itself (Figure 1). Because we used an excess of
Fv, there were six or seven free Fv molecules in the solution per
b-gal:Fv complex, and the background in the spaces between
the desired complexes was therefore filled with free Fv mole-
cules that, at the defocus used, show up as small black dots.
It was also possible to see the occasional GroEL structure (an
impurity from the scFv purification), showing either the 7-fold
top view or the striated edge view. Because these complexes
at a molecular weight (MW) of 700 kDa are only slight larger
than the combined b-gal (450 kDa) plus four Fv domains
(4x28kDa), which has a combined MW of 560 kDa, we were
careful to avoid picking any particles that looked like GroEL. A
typical micrograph contained 60 good b-gal complexes, but
possibly only one or two GroELs, so this was not a serious prob-
lem. Figure 1E shows some of the b-gal:Fv particles; these par-
ticles were are not visibly different from particles of b-gal alone,
as shown in Figure 1D. Nevertheless, the single-particle 3D
structure determination carried out using Frealign (Grigorieff,
2007) had no difficulty in orientation determination and 3D
map refinement, resulting in the map shown in Figure 2A.
A similar structure determination, calculated using Relion with
its gold standard Fourier shell correlation (FSC)-weighting
scheme (Scheres and Chen, 2012), is shown in Figure S2A
(available online). The difference maps in Figure 2A and Fig-622 Structure 22, 621–627, April 8, 2014 ª2014 The Authorsure S2A are contoured at two different
levels, showing the overall outline of the
Fv heavy and light chains at a low con-tour level (pink) and the two chains just resolved at a higher
contour level (green).
After docking of the rigid-body models, the FSC between map
and model is shown in Figure 2B, confirming the resolution esti-
mate of 13 A˚ obtained internally from the Frealign run. The 3D
map of b-gal alone (not shown), due to the lower background in
the absence of Fv, the greater number of particles, and the use of
subframe alignment and resolution-dependent weighting, had a
resolution of 5.4 A˚ (Figure 3), a value approximately double that
of the b-gal:Fv complex. This allowed more accurate magnifica-
tion determination and docking of the b-gal atomicmodel, result-
ing in more accurate identification of the residues involved in Fv
binding.
Residues involved in the contact with antibody and therefore in
mediating the rescue and stabilization of the AMEF mutated
b-gal are listed in Table 1. Although the b-gal:Fv map was
good enough to resolve the two Fv domains, it was not good
enough to identify which domain represented the heavy chain
and which represented the light chain. Nevertheless, it appears
that we have fortuitously chosen the correct locations for heavy
and light chains. As seen in Table 1, there are extensive contacts
between all the complementarity determining regions (CDRs) of
the heavy chain and domain 3 of b-gal, whereas there are mini-
mal contacts between the light chain and domain 1 of b-gal, con-
sisting of only a single possible contact between the light chain
CDR2 and domain 1 of b-gal. In the earlier mutagenesis selection
procedure (Martineau et al., 1998), six mutations throughout the
heavy chain and only one mutation in CRD2 of the light chain
contributed to the increased affinity. There is therefore excellent
correlation between the most extensive b-gal:Fv contact regions
seen in our map and the most extensive sites of the earlier
selected mutations (Martineau et al., 1998).
DISCUSSION
One of the hypotheses advanced originally, to explain the loss of
activity in mutant AMEF b-galactosidases and subsequent re-
gain of activity through AMEF, was that mutated enzymes were
dimers and that the antibodies bound to and stabilized an
epitope formed at the interface between two dimers (de Macario
et al., 1978), thus stimulating tetramer formation. In Figure 4, we
show the geometrical relationship between each Fv binding site
Figure 2. Surface-Contoured Structure of Complex between
scFv13R4 and b-gal
(A) Surface-contoured 3D map of b-gal alone (blue) and the difference map
between b-gal and the b-gal:Fv complex (pink) with docked coordinates 1F4A
of b-gal (Juers et al., 2000) and a typical Fv structure, taken from the 3A6B
complex (Yokota et al., 2010) between hen egg lysozyme and a similar Fv. The
maps were calculated using Frealign. The antibody domains are contoured at
two different contour levels, showing the whole Fv domain at a lower contour
level (pink) and the (just) resolved heavy and light chain densities at a higher
contour level (green).
(B) FSC plots for the b-gal:Fv complex. In blue squares, the FSC between
experimental maps each calculated from half of the single-particle images
shows a resolution at FSC 0.143 of 13 A˚. In red circles, FSC between the 3D
map and the density from the molecular model shows a resolution at FSC 0.5
of 15 A˚. Figure S2 shows a similar 3D map and FSC plot for the structure
computed using Relion.
Figure 3. FSC Plots for the Structure of b-gal without Antibody
(A) The FSC between two halves of the data for the structure of b-gal without
antibody is shown for the simple sum of image frames (red diamonds), for the
summed frames after alignment (green squares), and for the resolution-
dependent weighted sums (blue triangles), showing resolutions of 6.8, 6.3, and
5.4 A˚, respectively.
(B) The weighting factor proportional to the FSC at 7 A˚ resolution is shown
for 40 3D maps made from the first 40 single frames, each with a dose of
1 el/A˚2. Figure S3 shows two additional plots: a tilt pair parameter plot to
validate the overall procedure and high-resolution noise substitution to vali-
date resolution.
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only one of the four b-gal monomers, with the nearest distance
from any atom in the Fv to any atom in the next-nearest b-gal
subunit being 28 A˚. Because there is no contact between
scFv13R4 and any neighboring b-gal subunit, Fv binding can
therefore directly stabilize only the b-gal subunit to which it
binds. The locations of the AMEFmutation E358K used for selec-
tion of scFv13R4, and of another mutant G207D that is also acti-
vated by scFv13R4, are shown in Figure 4. The mutations E358K
and G207D are 16.5 and 22 A˚ distant from the nearest atom of
scFv13R4, respectively. The center of a typical bound substrateor inhibitor (e.g., isopropyl-thio-galactoside [IPTG], shown in Fig-
ure 4) is located 26 A˚ distant from the nearest atom of
scFv13R4. ScFv13R4 binds to a crevice in each subunit between
the N-terminal domain 1 of b-gal and the catalytic core domain 3.
Becausemutation E358K is in domain 3, andG207D is in domain
1, scFv13R4 binding can directly stabilize the region of the pro-
tein near both mutations. Our structure thus seems to indicate
that it is the direct stabilization of the active site within each sub-
unit by scFv13R4 that restores the activity. The tendency for
dissociation of tetramers into dimers in AMEF mutants, and the
subsequent stabilization of the tetramer by antibodies, is likely
to be an indirect consequence of the mutation, because the
epitope bound by scFv13R4 is located well away from the
dimer:dimer interface. The structure of b-gal shows that a loop
of16 amino acids from a neighboringmonomer extends acrossStructure 22, 621–627, April 8, 2014 ª2014 The Authors 623
Table 1. Possible Contacts between scFv13R4 (HyHEL-10
docked) and b-gal
Antibody Residues b-gal Residues
Light chain S56(S56) (CDR2) N55, E57 domain 1
Heavy chain E1(D1) (N-term) E57 domain 1
Heavy chain S30(T30) (CDR1) I576, K577, Y578 domain 3
Heavy chain N31, S33(S31, Y33)
(CDR1)
L362 domain 3
Heavy chain S33(Y33) (CDR1) D610 domain 3
Heavy chain S53(Y53) (CDR2) P361, H363, A609 domain 3
Heavy chain S54(S54) (CDR2) T612 domain 3
Heavy chain R71(R71) (outer loop) P584 domain 3
Heavy chain N73(T73) (outer loop) D579, G582, N583 domain 3
Heavy chain A74(S74) (outer loop) E580, N581 domain 3
Heavy chain S95, S96(W98, D99)
(CDR3)
Q370, domain 3
Residue numbering in the first column, such as S56, refers to the amino
acid sequence of scFv13R4 fromMartineau et al. (1998) and, in parenthe-
ses italicized, from the homologous docked lysozyme:HyHEL-10 Fv
structure, with PDB accession number 3A6B.
Structure
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part of the dimer:dimer interface. Mutations distant from the
dimerization interface can thus result in destabilization of the
tetramer.
It seems likely that the local region of the protein surface to
which the antibody binds will be held in a more rigid conforma-
tion than in the antibody-free state. This rigidification presum-
ably can then extend through the structure to an extent that
will reach the sites of the destabilizing mutations (16 A˚ distant),
and subsequently to both the active site (26 A˚ distant) and even
to the subunit:subunit interfaces (28 A˚ distant). Thus, there may
not be a clear yes or no answer to the question of whether the
antibody-mediated enzyme activation occurs by a mechanism
that is localized entirely to within the subunit to which it binds
or by a mechanism that indirectly increases the tetramer stabil-
ity. It is certain however that antibody binding does not primarily
stabilize the tetramer interface, but rather affects the entire pro-
tein. In general, it may not be easy to dissect the relative impor-
tance of these two possible ways of stabilizing the structure of
an enzyme or other multisubunit or multidomain protein by anti-
body binding. Clearly, part of the Fv binding energy is being
used to push the structure into a conformation that favors
both catalytic activity and tetramerization, particularly when
the magnitude of this binding energy is increased by powerful
in vitro mutagenesis followed by selection for growth that re-
quires enzyme activity.
The conclusions in this paper were anticipated by Laden et al.
(2002), even though they had no knowledge of the location of the
antibody binding. They explicitly suggested because the two
mutations might play a role in stabilizing the conformation of
the active site and because the locations of the mutations
were closer to the active site than to the dimer interface, that
the second mechanism (i.e., internal stabilization within each
subunit) was more likely to be correct. They also made the
argument that because the antibody is specific for the native
conformation of the enzyme, it should help constrain the enzyme624 Structure 22, 621–627, April 8, 2014 ª2014 The Authorsto its native, active state. Both these insights are confirmed and
extended by the present results.
Small single-domain antibodies, such as that studied in this
paper, are valuable in research, diagnostics, and therapy (Hol-
liger and Hudson, 2005). Understanding how an antibody binds
to a particular protein is essential for understanding the nature of
the epitope it recognizes. This understanding will help in the evo-
lution of higher affinity antibodies for better treatment of disease.
Growing crystals of protein-antibody complexes for analysis
by X-ray crystallography can be tricky, whereas single-particle
cryo-EM, as shown here with b-gal bound to scFV, can be rela-
tively straightforward. Even at moderate resolution, it is possible
to understand the biology behind the interactions. Analysis of
such protein complexes by cryo-EM may soon extend beyond
basic research to become a tool for rational drug development
by the pharmaceutical industry.
EXPERIMENTAL PROCEDURES
Expression and Purification of scFv13
The gene encoding scFv13R4 was expressed as described previously (Marti-
neau et al., 1998) in a pET 16b vector in E. coli strain PM12 (BL21 (DE3) pLysS
with a lacZ:Tn5 mutation. A single colony was inoculated into 6 ml of Luria
broth (LB) medium with ampicillin and chloramphenicol and grown for 10 hr
at 37C. Then, 1 ml of this culture was diluted into 50 ml of LB medium and
grown overnight at 37C. Cells (25 ml) were then diluted into 1 l of 2xYT
and grown at 37C at 200 rpm. Expression of scFv13R4 was induced at
optical density 600 of 0.5 with 0.4 mM IPTG, and then cells were again
grown overnight at 24C. Cells were harvested and lysed with an Emulsiflex
homogenizer (Avestin), and unbroken cells were removed by centrifugation
at 5,0003 g for 20min. The supernatant was loaded onto a nickel-nitrilotriace-
tic acid column (QIAGEN) pre-equilibrated with 25 mM Tris (pH 8.0) and 0.2 M
NaCl (buffer A). The columnwas washed with buffer A and buffer A with 10mM
imidazole. scFv13R4 was eluted with 0.2 M imidazole in buffer A. Protein frac-
tions at a concentration of 2 mg/ml were snap-frozen in liquid nitrogen and
stored at 80C.
Specimen Preparation for Cryo-EM and Imaging
Commercially available b-gal (Sigma catalog no. G3153) was used. For com-
plex formation, b-gal was mixed with scFv13R4 in a 1:10 stoichiometric ratio
(i.e., 2.5-fold excess) and incubated in ice for 1 hr. Then, 3 ml of b-gal, its com-
plex with scFv13R4, or scFv13R4 alone was applied to Quantifoil grids (1.2 mm
holes), blotted for 5 s, and plunge-frozen in liquid ethane at near liquid nitrogen
temperature, using an environmental plunge-freeze apparatus (Bellare et al.,
1988). Grids were transferred into a Polara G2 electron microscope (FEI),
and low-dose images were recorded on a Falcon II CMOS direct electron de-
tector (FEI) at 300 keV and 80,2403 magnification (59,0003 nominal), with
specimen temperature at 186C. Images were recorded with a range of
defocus values between 1.5 and 5.0 mm, and typical exposures times of 4 s.
The pixel size is 14 mm on the Falcon detector, translating into a sampling
rate of 1.75 A˚/pixel. Nominal pixel sizes required later refinement by up to
3% against an atomic model from X-ray crystallography (Dugdale et al.,
2010) to obtain the correct magnification.
Image Processing and 3D Reconstruction
We selected 49 images out of a total of 52 recorded based on good ice thick-
ness and reasonable particle visibility. A total of 2,965 particles were picked by
hand using Ximdisp (Smith, 1999). CTFs were estimated using CTFFIND3
(Mindell and Grigorieff, 2003), boxed particle densities were floated and
normalized using BOXIMAGE (Crowther et al., 1996), and 3Dmapswere calcu-
lated using Frealign (Grigorieff, 2007). Part of a typical micrograph is shown in
Figure 1A. Comparison with a similar micrograph of b-gal without scFv, shown
in Figure 1B, shows that the images of the complex look much noisier because
the free 28 kDa scFv particles show up as a background of smaller black dots
(Figure 1C).
Figure 4. Geometrical Relationship between the Fv Antibody and Key Residues in the Enzyme
Each Fv antibody binds to an extended surface of one b-gal subunit that is made up of part of the N-terminal domain 1 and part of domain 3, the core b-barrel
catalytic domain that lies at the heart of each of the b-gal subunits. The illustration shows the entire structure (top left); one b-gal subunit with each of the five
domains in different colors (top right); and parts of domains 1 and 3 from one b-gal subunit (bottom right and bottom left), rotated 30 to the left, showing the
region that is in contact with the (red) Fv. The amino acid E358K (yellow) that is mutated in AMEF959, the amino acid G207D (yellow) that is mutated in AMEF645,
and the two active-site residues E461 andH540 are labeled. A purple atomicmodel of IPTG (fromPDB 3DYO) shows the location of the substrate binding site. The
most extensive contacts, shown at bottom left and listed in Table 1, are between the Fv heavy chain and domain 3 of b-gal, with the antibody surface shown in
dark gray and the b-gal surface in cyan. Figure S4 shows a stereo plot of the same region.
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E. coli b-gal structure (Dugdale et al., 2010), using Protein Data Bank (PDB)
coordinates 1F4A (Juers et al., 2000). A rough correction for the fact that the
real specimen is embedded in a solvent (amorphous ice) with a density of
80% of that of protein was applied by subtracting from a map calculated
from atomic coordinates in vacuo; another map with a B-factor of 2,000;
and a scale factor of 0.8. This solvent correction affects only the low-resolution
structure: its effect falls to about a third at 20 A˚ and is negligible by 10 A˚. The
80% factor is a rough approximation for the amount of electron scattering by
ice compared with protein, although a slightly lower value of 72% was esti-
mated previously (Rosenthal and Henderson, 2003). Note that we could
equally well have used a good experimental cryo-EMmap as the starting refer-
ence (Henderson et al., 2011).
The particle images were binned 2 3 2 to give a nominal pixel size of 3.5A˚,
corresponding to a potential resolution at Nyquist of 7.0 A˚. A high-resolution
cut-off of 14 A˚ was used during refinement of the particle position and
orientation parameters to avoid the possibility of overfitting (Chen et al.,
2013). The density representing the antibody domain started to appear in
the first cycle of determination of particle orientation and position. The
map did not improve after 12 cycles, showing a resolution of 13 A˚ at an
FSC value of 0.143. The density representing only the antibody domains
was determined by subtracting a 3D map of b-gal from the 3D map of the
b-gal:Fv complex, with both maps on the same scale and with no B-factorsharpening (Rosenthal and Henderson, 2003). The antibody domains had a
peak density of approximately eight times the root mean square density in
the difference map and more than 90% of the peak density in the b-gal
region of the map, so we estimate the occupancy to be about 90%. Later
calculation of FSC between the map and an atomic model of the b-gal:Fv
complex with variable Fv occupancy also gave best agreement with 90%
occupancy.
Rigid-Body Docking of Atomic Models
Molecular models representing b-gal (Juers et al., 2000) and a typical Fv
domain, HyHEL-10 (Yokota et al., 2010), were docked into the 3D density
map using Chimera (Pettersen et al., 2004), and the resulting structure is
shown in Figure 2. The Fv from the lysozyme:HyHEL-10 complex was chosen
because the original Fab complex (Padlan et al., 1989) was one of the first-
known structures of an antibody bound to its macromolecular antigen. The
variable domains also have 40% sequence identity with scFv13R4, with
only small deletions in four of the six complementarity determining regions
(see Figure S1). The PDB accession numbers for the b-gal and the Fv coor-
dinates used are 1F4A and 3A6B, respectively. At an appropriate contour
level, the two domains of the Fv structure could be resolved, but even after
sharpening it was not possible to assign which of the two variable domains
within the Fv structure corresponded to the light chain and heavy chain
sequences.Structure 22, 621–627, April 8, 2014 ª2014 The Authors 625
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We also include in this paper a description of the method used to produce the
cryo-EM map of the uncomplexed b-gal. Eighty-nine images of b-gal alone
were recorded with simultaneous acquisition of individual movie frames in
the rolling-shutter mode of data acquisition by the Falcon CMOS detector.
Typically, exposures were recorded as full-resolution movies that contained
up to 80 frames (at 18 Hz frame rate). The exposures were saved as both single
images that consisted of the sum of all the frames and as a full-resolution
movie. Exposures varied from 2 to 5 s (34–80 electrons [el]/A˚2). Using Ximdisp,
43,000 single particles were manually picked. Movement of these particles
during the exposure was tracked using a noise-weighted cross-correlation.
In this cross-correlation, a 2563 256 pixel boxwas placed about each particle,
and the motion of a particle relative to the self-consistent average particle
calculated. The cross-correlation was calculated using Fourier components
between 1/200 and 1/25 A˚1 and care was taken to avoid the residual fixed
pattern signal from the detector. Because b-gal molecules are relatively small,
the signal from individual frames was too weak to reliably determine a cross-
correlation peak. A reliable peak could however be determined by using
running averages over 11 frames. These calculations indicated that neigh-
boring particles moved together, so final movements were determined from
the combined cross-correlation estimate from the particle and all particles
within a radius of 1,000 A˚ from the center of the particle. The nature of the par-
ticles is not important for movement determination, so additional particles
were selected from the images using an automated particle picker. With the
additional signal from the neighboring particles, the number of frames in the
running average was reduced to five. The resolution of the 3D map calculated
from single-particle images obtained after this alignment improved from 6.8 to
6.3 A˚, as shown in Figure 3A). It was also possible to calculate 3D maps from
single frames of all the particles and to examine the information content of
each of the frames at different spatial frequencies from the FSC. Cross-corre-
lation at 7 A˚ resolution between the 3D map obtained from each frame and
the map from the summed frames is shown in Figure 3B. It shows that the first
three frames, with each frame having an exposure of 1 el/A˚2, had lower infor-
mation content at 7 A˚ resolution than frames 4–9, which had the most infor-
mation. The information content of subsequent frames (i.e., frames 10–40)
appeared to follow the decay expected from radiation damage at 7 A˚ reso-
lution and liquid nitrogen temperature that was observed previously by
following the decay of electron diffraction patterns from 2D crystals of
bacteriorhodopsin (Stark et al., 1996). By applying resolution-dependent
weighting to each frame according to the information content, the resolution
of the final 3D map was further improved to 5.4 A˚, as shown in Figure 3A.
The resolution-dependent weighting was applied using TWOFILE (Crowther
et al., 1996) to multiply the Fourier transform of each frame of the aligned
images of each particle by a resolution-dependent number derived from the
FSC curve for the 3D maps from the individual frames described above. The
frame- and resolution-dependent multipliers were produced by a program
called MAKE_RESOL_WEIGHTS that is available on request. The weighted
Fourier transforms of the individual frames were then back-transformed and
summed to produce the optimized single-particle images. Using this proce-
dure, the later frames, for example from 40 to 80 el/A˚2, contributed to this final
map only at lower resolution.
Map and Model Deposition
The maps of the b-gal:scFv complex, b-gal alone, and the antibody difference
map have been deposited in Electron Microscopy Data Bank with accession
number EMD-2548. The model of the b-gal:scFv complex has been deposited
in PDB with accession number 4CKD.SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and can be found with this
article online at http://dx.doi.org/10.1016/j.str.2014.01.011.
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